J 2021

Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: A case report

SIN, Robin and Denisa ŠTRUNCOVÁ

Basic information

Original name

Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: A case report

Authors

SIN, Robin (203 Czech Republic) and Denisa ŠTRUNCOVÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

World Journal of Clinical Cases, PLEASANTON, BAISHIDENG PUBLISHING GROUP INC, 2021, 2307-8960

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30218 General and internal medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 1.534

RIV identification code

RIV/00216224:14110/21:00124181

Organization unit

Faculty of Medicine

DOI

UT WoS

000727979500031

Keywords in English

SARS-CoV-2; COVID-19; mRNA vaccine; Complication of vaccination; Status epilepticus; Case report

Tags

Tags

International impact, Reviewed
Změněno: 3/3/2022 13:21, Mgr. Tereza Miškechová

Abstract

V originále

BACKGROUND We present a rare case of status epilepticus in a 56-year-old man which arose as a complication after vaccination with the coronavirus disease 2019 (COVID-19) mRNA-1273 vaccine. The patient's history included well-compensated secondary epilepsy. The root cause of the situation was a fever which had developed as a side effect of the vaccination. CASE SUMMARY A 56-year-old man received the first dose of mRNA-1273 vaccine against the severe acute respiratory syndrome-coronavirus-2. The vaccine was administered intramuscularly (100 mg, 0.5 mL). The next morning the man was found to be suffering from fever and headaches while at the same time experiencing general weakness. He lost consciousness suddenly and experienced generalized clonic seizures which turned into status epilepticus. When the Emergency Medical Service arrived the patient was unconscious with spontaneous breathing and generalized clonic seizures. It was necessary to administer diazepam repeatedly. It was also necessary to administer high doses of levetiracetam and temporary propofol. The status epilepticus was brought under control approximately 90 min after the patient's transport to the Emergency Department. A follow-up electroencephalogram no longer revealed abnormal indications of epileptic fit. The patient was temporarily hospitalized in the Intensive Care Unit and after seven days care was discharged without any further apparent effects. CONCLUSION There is currently no specific treatment against COVID-19. Therefore, the benefits of COVID-19 vaccine protection outweigh the risks.